EMJ Oncology 9 [Supplement 4] . 2021

In this issue

OVARIAN cancer is the seventh most commonly diagnosed malignancy among women worldwide, and the gynaecologic cancer with the worst prognosis and highest mortality. This is because of its resistance to common chemotherapeutic agents, vague and non-specific symptoms, and the lack of effective screening strategies for early detection. However, new research has suggested that poly(ADP-ribose) polymerase (PARP) inhibitors could potentially transform the treatment landscape of advanced ovarian cancer.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?